April 5, 2024 11:09 AM EDT

Protara's $45M placement; Plus, news about Eupraxia and GenSight

ENDPOINTS

Protara Therapeutics raises $45M private placement: The oversubscribed financing transaction is set to close April 10. The proceeds should extend the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Protara's $45M placement; Plus, news about Eupraxia and GenSight

ENDPOINTS

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Amgen names Stanford geneticist and biotech founder to CSO post

Jazz wins approval for bispecific in biliary tract cancer

Are programs with compounded GLP-1s safe for your population?

Pro­tara's $45M place­ment; Plus, news about Eu­prax­ia and Gen­Sight

ENDPOINTS

Sign up to read this article for free.

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Protara's $45M placement; Plus, news about Eupraxia and GenSight

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Amgen names Stanford geneticist and biotech founder to CSO post

Jazz wins approval for bispecific in biliary tract cancer

Are programs with compounded GLP-1s safe for your population?